NCT01527539View on ClinicalTrials.gov

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 23, 2001

Primary Completion Date

October 12, 2004

Study Completion Date

October 12, 2004

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)

Trial Locations (4)

B3H 1V7

Novo Nordisk Investigational Site, Halifax

M5B 1W8

Novo Nordisk Investigational Site, Toronto

T5H 3V9

Novo Nordisk Investigational Site, Edmonton

N8W 3K2

Novo Nordisk Investigational Site, Windsor

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01527539 - Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter